Welcome to our dedicated page for Apellis Pharmace SEC filings (Ticker: APLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Apellis Pharmaceuticals, Inc. (APLS) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a commercial-stage biopharmaceutical issuer listed on the Nasdaq Global Select Market, Apellis uses filings such as Forms 10-K, 10-Q, 8-K, and others to report on its business, financial condition, risk factors, and material events related to its complement-based therapies SYFOVRE and EMPAVELI/Aspaveli.
In these filings, investors can review detailed information on revenue from SYFOVRE and EMPAVELI, research and development spending for ophthalmology and rare disease programs, and the status of key clinical trials such as GALE and VALIANT. Risk factor and management discussion sections typically describe the scientific and regulatory considerations associated with targeting C3 in geographic atrophy, C3 glomerulopathy, primary IC-MPGN, and paroxysmal nocturnal hemoglobinuria.
Current reports on Form 8-K, such as the Royalty Buy-Down Agreement with Swedish Orphan Biovitrum AB (Sobi), document material definitive agreements that affect Apellis’ economics, including ex-U.S. royalty structures for Aspaveli and related financing consents. These filings help clarify how collaborations and capital arrangements support the company’s commercialization and pipeline strategy.
On Stock Titan, Apellis filings are updated in near real time as they are posted to EDGAR. AI-powered summaries highlight key points from lengthy documents, helping readers quickly understand topics like royalty arrangements, cash runway, product revenue trends, and major clinical or regulatory milestones. Users can also review Forms 4 and other insider transaction reports to monitor trading activity by Apellis directors and executives, alongside proxy and governance disclosures that describe compensation and board oversight. This page is a central resource for analyzing the regulatory record behind APLS stock.
Apellis Pharmaceuticals’ Chief People Officer Kelley Boucher received an equity grant of 30,146 shares of common stock in the form of restricted stock units on January 28, 2026. The award vests 25% each year over four years, subject to continued service.
Following this grant, Boucher beneficially owns 127,804 shares of Apellis common stock in direct ownership. This filing reflects routine equity-based compensation rather than an open-market purchase or sale.
Apellis Pharmaceuticals VP and Chief Accounting Officer James George Chopas reported an equity grant of 16,150 shares of common stock on January 28, 2026. The Form 4 shows the transaction coded as an acquisition at a price of $0 per share, tied to a restricted stock unit award.
According to the footnote, this award consists of restricted stock units that vest 25% each year over four years from the grant date, contingent on continued service. Following this grant, Chopas is shown as directly beneficially owning 65,955 shares of Apellis common stock.
Apellis Pharmaceuticals’ Chief Business & Strat Officer Mark DeLong received an award of 36,606 shares of common stock on January 28, 2026 as a restricted stock unit grant. These RSUs vest 25% each year over four years, contingent on continued service. Following this grant, DeLong directly beneficially owns 114,959 shares of Apellis common stock.
Apellis Pharmaceuticals Chief Scientific Officer receives new equity grant. Pascal Deschatelets was awarded 25,840 shares of Apellis common stock on January 28, 2026 as a restricted stock unit grant at a price of $0 per share. These units vest 25% each year over four years, conditioned on continued service. Following this award, he beneficially owns 1,177,222 shares of Apellis common stock held directly.
Apellis Pharmaceuticals’ Chief Research and Development officer Leslie Meltzer reported a stock-based compensation grant. On January 28, 2026, Meltzer received 45,220 shares of Apellis common stock at a price of $0 per share, reflecting a restricted stock unit award.
Following this grant, Meltzer beneficially owns 107,024 shares directly. The award vests 25% each year over four years from the grant date, and vesting is conditioned on continued service with the company.
Apellis Pharmaceuticals reported that Chief Technical Officer Nur Nicholson received a grant of 45,220 shares of common stock on January 28, 2026. The shares were awarded at a price of $0 per share as part of an equity compensation program.
According to the footnote, this award is in the form of restricted stock units that vest 25% each year over four years from the grant date, subject to continued service. Following this grant, Nicholson beneficially owns 116,338 shares of Apellis common stock in direct ownership.
Apellis Pharmaceuticals’ chief financial officer, Timothy E. Sullivan, reported receiving an award of 58,140 shares of common stock on January 28, 2026 at a price of $0 per share, representing a restricted stock unit grant that vests 25% annually over four years, subject to continued service.
Following the award, he reports 152,041 shares of Apellis common stock held directly. An additional 60,396 shares are reported as indirectly held through The Timothy E Sullivan Irrevocable Trust of 2023, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Apellis Pharmaceuticals reported that its General Counsel, David O. Watson, received a grant of 55,986 shares of common stock on January 28, 2026, at a price of $0, described as a restricted stock unit award vesting 25% annually over four years, subject to continued service. Following this award, he directly beneficially owns 144,517 shares of common stock. He also reports indirect holdings of 10,000 shares in a custodial account for his minor children and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023, for which he disclaims beneficial ownership except for any pecuniary interest.
Apellis Pharmaceuticals CEO Cedric Francois reported a new equity grant of 195,952 shares of common stock on January 28, 2026, awarded as restricted stock units at $0 per share. Following this grant, he directly holds 481,997 Apellis common shares.
The RSU award vests 25% each year over four years from the grant date, subject to continued service. Additional Apellis shares are held by several trusts, including The Cedric Francois Irrevocable Trust of 2023 - 2, The Cedric Francois Irrevocable Trust of 2023, The Francois Grossi Trust, and The Francois-DuBois Educational Trust, where Francois disclaims beneficial ownership except for any pecuniary interest.
Apellis Pharmaceuticals Chief Medical Officer Caroline Baumal reported a routine insider transaction involving company common stock. On January 22, 2026, she sold 2,797 shares of Apellis common stock at a price of $21.7654 per share. According to the footnote, these shares were sold specifically to cover tax withholding obligations arising from restricted stock units that were released on January 21, 2026.
After this sale, Baumal beneficially owned 86,527 Apellis shares, all held directly. The filing characterizes this as a tax-related sale rather than a discretionary open-market reduction in her overall ownership.